Cardiff Oncology

CARDIFF ONCOLOGY INC

Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Men,,Tablet,And,Barista,With,Pride,,Small,Business,And,Colleagues

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Small Cap

Econ #s

Economics

Small Business

Tech

ETFs

CRDF

CRVO

GOEV

NRDY

SCLX

UNFI

Small businesses are entering the holiday season with newfound confidence and momentum, thanks to post-election policies and reduced inflation.

US Small Business Optimism Hits 3-Year High As Election Results &#39;Signal A Major Shift&#39;

Biotech

News

Health Care

Movers

General

Cardiff Oncology&#39;s CRDF-004 trial shows promising onvansertib results in RAS-mutated mCRC patients, with higher tumor response rates and a strong safety profile.

What&#39;s Going On With Cardiff Oncology Stock On Tuesday?

Earnings

Penny Stocks

Eurozone

Commodities

Global

Intraday Update

Markets

Trading Ideas

BCDA

BIVI

DECK

JOAN

QNRX

RNLX

SMCI

ZION

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 edging lower on Monday.

The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18% to 16,245.77. The S&amp;P 500 also fell, dropping, 0.01% to 5,137.05.

Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher

Cardiff Oncology Inc

Press Releases

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Financing

IPOs

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Stocks to Watch in December 2025: LDTC, CPIX, PNPN.V, ZEO, and More Inside

Opinion

Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Cardiff Oncology to Present at Upcoming Investor Conferences

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

ABBV

ALXO

CKPT

CLLXF

CMRX

CPIX

EXEL

KGFMF

LDTC

ONCY

PNPNF

PRSO

PSNL

STRRF

TSX:ONC

TSXV:CNX

TSXV:KFR

TSXV:PNPN

TSXV:VRR

VRRCF

VSTM

Abeona Therapeutics

Anika Therapeutics

Cidara Therapeutics

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

Cargo Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Foghorn Therapeutics

Genfit

Inhibrx Biosciences

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

ITeos Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Neurogene

Nuvectis Pharma

Ocugen

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

AVITA Medical

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Tevogen Bio Holdings

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

XOMA Royalty

Y-mAbs Therapeutics

HC Wainwright & Co.

Piper Sandler

Craig-Hallum

Baird

Comments

Cardiff Oncology

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga